Filter Results:
(128)
Show Results For
- All HBS Web
(546)
- People (2)
- News (136)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(546)
- People (2)
- News (136)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Sort by
- April 2009 (Revised October 2010)
- Case
Bob Beall at the Cystic Fibrosis Foundation
By: Robert Steven Kaplan and Sophie Hood
Bob Beall is the Chief Executive Officer of the Cystic Fibrosis Foundation (CFF). CFF is an extremely successful organization, but Beall has to determine how to manage the organization through the financial crisis of 2008-2009. In this situation, donations are likely... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Philanthropy and Charitable Giving; Governing and Advisory Boards; Leadership; Crisis Management; Nonprofit Organizations
Kaplan, Robert Steven, and Sophie Hood. "Bob Beall at the Cystic Fibrosis Foundation." Harvard Business School Case 409-107, April 2009. (Revised October 2010.)
- March 2024
- Case
Biomanufacturing Decentralization by Stämm
By: Paul A. Gompers, Jenyfeer Martínez Buitrago and Mariana Cal
In Buenos Aires, Argentina, cousins Llamazares and D’Alvia founded Stämm, a startup based on the idea of decentralizing biomanufacturing processes and downsizing biotech facilities. After raising its seed and series A rounds, and while finalizing its series B round in... View Details
Keywords: Business Model; Business Startups; Entrepreneurship; Venture Capital; Selection and Staffing; Technological Innovation; Science-Based Business; Business Strategy; Commercialization; Growth and Development Strategy; Product Launch; Research and Development; Biotechnology Industry; Latin America; South America; Argentina; Buenos Aires
Gompers, Paul A., Jenyfeer Martínez Buitrago, and Mariana Cal. "Biomanufacturing Decentralization by Stämm." Harvard Business School Case 824-190, March 2024.
- February 2022
- Case
Leading The UK Vaccine Task Force
By: Amy C. Edmondson and Claudia Pienica
This case describes the first six months of the UK Vaccine Taskforce, under the leadership of Kate Bingham. With a career spent in the private sector as a biotech investor, Bingham’s appointment within the government was considered unusual. The overarching brief given... View Details
Keywords: COVID-19; Vaccine; Government; Health Pandemics; Health Care and Treatment; Science; Innovation and Invention; Groups and Teams; Leadership; Decision Making; Government and Politics; Health; Innovation and Management; Governance; Change; Government Administration; Health Industry; Financial Services Industry; Public Administration Industry; Europe; United Kingdom
Edmondson, Amy C., and Claudia Pienica. "Leading The UK Vaccine Task Force." Harvard Business School Case 622-079, February 2022.
- February 2006
- Case
Michelle Levene (A)
Michelle Levene discovers that she is pregnant a few days before receiving an offer for her dream job. The new position would require Levene to travel extensively, something she would not be able to do towards the end of the pregnancy and while caring for a newborn.... View Details
Keywords: Work-Life Balance
Casciaro, Tiziana E., and Victoria Winston. "Michelle Levene (A)." Harvard Business School Case 406-083, February 2006.
- January 2006
- Case
Jack Strang at SequenceLabs
By: Mukti Khaire, John J. Gabarro and Lynda M. Applegate
How can entrepreneur manage his firm if things go wrong despite having a great idea, a solid team, and financial backing? Jack Strang founded a biotech firm with his friend Peter Evans, to develop molecular pathway-based "cures" for metabolic disorders. The idea was... View Details
- June 2021
- Case
uBiome
By: Thomas R. Eisenmann and Olivia Graham
uBiome provided clinical tests that sequenced the DNA of human microbiome samples, providing data on health conditions directly to consumers or to prescribing physicians. Founded in 2012, the San Francisco-based startup raised $105 million from top-tier venture capital... View Details
- June 2013
- Article
Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration
By: Umit Ozmel, Jeffrey J. Reuer and Ranjay Gulati
In this paper, we examine the contingent effects of signals generated by different types of networks on new ventures' formation of future strategic alliances. We argue that the signaling value of a given tie in reducing adverse selection is more pronounced when another... View Details
Ozmel, Umit, Jeffrey J. Reuer, and Ranjay Gulati. "Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration." Academy of Management Journal 56, no. 3 (June 2013): 852–866.
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Pharmaceutical Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details
Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry
Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Biotechnology Industry; Pharmaceutical Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- 15 May 2007
- First Look
First Look: May 15, 2007
Working PapersI'll Have the Ice Cream Soon and the Vegetables Later: Decreasing Impatience over Time in Online Grocery Orders Authors:Todd Rogers, Katherine L. Milkman, and Max H. Bazerman Abstract How do decisions for the near future differ from decisions for the... View Details
Keywords: Martha Lagace
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- December 2008 (Revised January 2011)
- Case
Arcadia Biosciences: Seeds of Change
By: Arthur A. Daemmrich, Forest L. Reinhardt and Mary Louise Shelman
Arcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September 2008. The company... View Details
Keywords: Business Startups; Entrepreneurship; Growth and Development Strategy; Environmental Sustainability; Science-Based Business; Climate Change; Agriculture and Agribusiness Industry; Biotechnology Industry; China; India; California
Daemmrich, Arthur A., Forest L. Reinhardt, and Mary Louise Shelman. "Arcadia Biosciences: Seeds of Change." Harvard Business School Case 709-019, December 2008. (Revised January 2011.)
- 15 Dec 2009
- First Look
First Look: Dec. 15, 2009
http://cb.hbsp.harvard.edu/cb/product/510037-PDF-ENG Tengion: Bringing Regenerative Medicine to Life Elie Ofek and Polly Ross RibattHarvard Business School Case 510-031 Tengion is a young biotech company that is at the frontier of... View Details
Keywords: Martha Lagace
- 15 Oct 2013
- First Look
First Look: October 15
science to consumers. It found it increasingly necessary to direct more of its resources towards marketing, including a major investment in Jennifer Aniston as its celebrity spokesperson. Were they becoming less of a biotech company and... View Details
Keywords: Sean Silverthorne
- October 2001 (Revised March 2002)
- Case
Perlegen Sciences
By: Linda A. Hill and Nicole Tempest
As a biotech start-up company involved in studying human genomes, Perlegen needed to develop an organization that fostered innovation and teamwork among a group of highly trained professionals from both the science and technology fields. Perlegen's CEO, Brad Margus,... View Details
Keywords: Innovation Leadership; Groups and Teams; Management Teams; Problems and Challenges; Business Startups; Genetics; Talent and Talent Management; Innovation Strategy; Biotechnology Industry
Hill, Linda A., and Nicole Tempest. "Perlegen Sciences." Harvard Business School Case 402-026, October 2001. (Revised March 2002.)
- June 2014 (Revised February 2017)
- Case
Kathy Giusti and the Multiple Myeloma Research Foundation
By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its... View Details
Keywords: Philanthropy; Philanthropy Funding; Entrepreneurship; Health Care; Management Styles; Personalized Medicine; Health Care Outcomes; Cancer; Cancer Care In The U.S.; Personal Care; Leadership; Leading Change; Social Entrepreneurship; Philanthropy and Charitable Giving; Health Care and Treatment; Leadership Style; Management Style; Management Skills; Growth and Development Strategy; Business Strategy; Health; Health Industry; United States; Canada; Spain
Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)
- 11 Apr 2011
- Lessons from the Classroom
Teaching a ‘Lean Startup’ Strategy
in the clean tech and biotech fields, both of which often require a great deal of time and capital to create any workable product. The same is true of the transportation industry—inventor Dean Kamen's Segway, for example, or startup... View Details
- 30 Mar 2021
- Research & Ideas
Commuting Hurts Productivity and Your Best Talent Suffers Most
workers’ subjective well-being,” the researchers write. How can companies ease the commuting pain? While Wu is quick to note that some “knowledge work” depends on in-person collaboration, including medical and biotech research, he says... View Details
Keywords: by Lane Lambert
- 09 Jan 2012
- Research & Ideas
Location, Location, Location: The Strategy of Place
they don't have much choice but to cozy near the competition, especially when they need to plug into unique knowledge that exists in certain areas. Biotech companies, for instance, often operate close to top-notch universities to interact... View Details
Keywords: by Dina Gerdeman